Taken together, the results indicated that TMEM166 deletion promotes cell proliferation dependent on PERK activation and that IRE1 and ATF6 activation confers HCC cells with sorafenib resistance. The gene discussed is EVA1A; the disease is hepatocellular carcinoma.